|
1
|
GLOBOCAN 2012: Estimated Cancer Incidence,
Mortality and Prevalence Worldwide in 2012. v1.0. IARC CancerBase
No. 11. IARC; Lyon: 2012
|
|
2
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Nashimoto A, Akazawa K, Isobe Y, Miyashiro
I, Katai H, Kodera Y, Tsujitani S, Seto Y, Furukawa H, Oda I, et
al: Gastric cancer treated in 2002 in Japan: 2009 annual report of
the JGCA nationwide registry. Gastric Cancer. 16:1–27. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tan HL, Chia CS, Tan GH, Choo SP, Tai DW,
Chua CW, Ng MC, Soo KC and Teo MC: Gastric peritoneal
carcinomatosis-a retrospective review. World J Gastrointest Oncol.
9:121–128. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Dahdaleh FS and Turaga KK: Evolving
treatment strategies and outcomes in advanced gastric cancer with
peritoneal metastasis. Surg Oncol Clin N Am. 27:519–537. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kitayama J, Ishigami H, Yamaguchi H,
Sakuma Y, Horie H, Hosoya Y, Lefor AK and Sata N: Treatment of
patients with peritoneal metastases from gastric cancer. Ann
Gastroenterol Surg. 2:116–123. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fujimoto S, Takahashi M, Mutou T,
Kobayashi K, Toyosawa T, Isawa E, Sumida M and Ohkubo H: Improved
mortality rate of gastric carcinoma patients with peritoneal
carcinomatosis treated with intraperitoneal hyperthermic
chemoperfusion combined with surgery. Cancer. 79:884–891. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kuramoto M, Shimada S, Ikeshima S, Matsuo
A, Yagi Y, Matsuda M, Yonemura Y and Baba H: Extensive
intraoperative peritoneal lavage as a standard prophylactic
strategy for peritoneal recurrence in patients with gastric
carcinoma. Ann Surg. 250:242–246. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhu BY, Yuan SQ, Nie RC, Li SM, Yang LR,
Duan JL, Chen YB and Zhang XS: Prognostic factors and recurrence
patterns in T4 gastric cancer patients after curative resection. J
Cancer. 10:1181–1188. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kodera Y, Nakanishi H, Ito S, Yamamura Y,
Kanemitsu Y, Shimizu Y, Hirai T, Yasui K, Kato T and Tatematsu M:
Quantitative detection of disseminated free cancer cells in
peritoneal washes with real-time reverse transcriptase-polymerase
chain reaction: A sensitive predictor of outcome for patients with
gastric carcinoma. Ann Surg. 235:499–506. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang JY, Lin SR, Lu CY, Chen CC, Wu DC,
Chai CY, Chen FM, Hsieh JS and Huang TJ: Gastric cancer cell
detection in peritoneal lavage: RT-PCR for carcinoembryonic antigen
transcripts versus the combined cytology with peritoneal
carcinoembryonic antigen levels. Cancer Lett. 223:129–135. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fujiwara Y, Doki Y, Taniguchi H, Sohma I,
Takiguchi S, Miyata H, Yamasaki M and Monden M: Genetic detection
of free cancer cells in the peritoneal cavity of the patient with
gastric cancer: Present status and future perspectives. Gastric
Cancer. 10:197–204. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
van Niel G, D'Angelo G and Raposo G:
Shedding light on the cell biology of extracellular vesicles. Nat
Rev Mol Cell Biol. 19:213–228. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lu J, Getz G, Miska EA, Alvarez-Saavedra
E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA,
et al: MicroRNA expression profiles classify human cancers. Nature.
435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Croce CM: Causes and consequences of
microRNA dysregulation in cancer. Nat Rev Genet. 10:704–714. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kosaka N and Ochiya T: Unraveling the
mystery of cancer by secretory microRNA: Horizontal microRNA
transfer between living cells. Front Genet. 2:972011.PubMed/NCBI
|
|
17
|
Matsumura T, Sugimachi K, Iinuma H,
Takahashi Y, Kurashige J, Sawada G, Ueda M, Uchi R, Ueo H, Takano
Y, et al: Exosomal microRNA in serum is a novel biomarker of
recurrence in human colorectal cancer. Br J Cancer. 113:275–281.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang N, Wang L, Yang Y, Gong L, Xiao B and
Liu X: A serum exosomal microRNA panel as a potential biomarker
test for gastric cancer. Biochem Biophys Res Commun. 493:1322–1328.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kwon JJ, Factora TD, Dey S and Kota J: A
systematic review of miR-29 in cancer. Mol Ther Oncolytics.
12:173–194. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Alizadeh M, Safarzadeh A, Beyranvand F,
Ahmadpour F, Hajiasgharzadeh K, Baghbanzadeh A and Baradaran B: The
potential role of miR-29 in health and cancer diagnosis, prognosis,
and therapy. J Cell Physiol. 234:19280–19297. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Witwer KW, Buzas EI, Bemis LT, Bora A,
Lässer C, Lötvall J, Nolte-'t Hoen EN, Piper MG, Sivaraman S, Skog
J, et al: Standardization of sample collection, isolation and
analysis methods in extracellular vesicle research. J Extracell
Vesicles. 2:203602013. View Article : Google Scholar
|
|
22
|
Andersen CL, Jensen JL and Orntoft TF:
Normalization of real-time quantitative reverse transcription-PCR
data: A model-based variance estimation approach to identify genes
suited for normalization, applied to bladder and colon cancer data
sets. Cancer Res. 64:5245–5250. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kosaka N, Iguchi H and Ochiya T:
Circulating microRNA in body fluid: A new potential biomarker for
cancer diagnosis and prognosis. Cancer Sci. 101:2087–2092. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Joyce DP, Kerin MJ and Dwyer RM:
Exosome-encapsulated microRNAs as circulating biomarkers for breast
cancer. Int J Cancer. 139:1443–1448. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Toiyama Y, Okugawa Y, Fleshman J, Richard
Boland C and Goel A: MicroRNAs as potential liquid biopsy
biomarkers in colorectal cancer: A systematic review. Biochim
Biophys Acta Rev Cancer. 1870:274–282. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Nedaeinia R, Manian M, Jazayeri MH,
Ranjbar M, Salehi R, Sharifi M, Mohaghegh F, Goli M, Jahednia SH,
Avan A, et al: Circulating exosomes and exosomal microRNAs as
biomarkers in gastrointestinal cancer. Cancer Gene Ther. 24:48–56.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Shrestha S, Hsu SD, Huang WY, Huang HY,
Chen W, Weng SL and Huang HD: A systematic review of microRNA
expression profiling studies in human gastric cancer. Cancer Med.
3:878–888. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Link A and Kupcinskas J: MicroRNAs as
non-invasive diagnostic biomarkers for gastric cancer: Current
insights and future perspectives. World J Gastroenterol.
24:3313–3329. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tokuhisa M, Ichikawa Y, Kosaka N, Ochiya
T, Yashiro M, Hirakawa K, Kosaka T, Makino H, Akiyama H, Kunisaki C
and Endo I: Exosomal miRNAs from peritoneum lavage fluid as
potential prognostic biomarkers of peritoneal metastasis in gastric
cancer. PLoS one. 10:e01304722015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Mott JL, Kobayashi S, Bronk SF and Gores
GJ: mir-29 regulates Mcl-1 protein expression and apoptosis.
Oncogene. 26:6133–6140. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Fabbri M, Garzon R, Cimmino A, Liu Z,
Zanesi N, Callegari E, Liu S, Alder H, Costinean S,
Fernandez-Cymering C, et al: MicroRNA-29 family reverts aberrant
methylation in lung cancer by targeting DNA methyltransferases 3A
and 3B. Proc Natl Acad Sci USA. 104:15805–15810. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Gong J, Li J, Wang Y, Liu C, Jia H, Jiang
C, Wang Y, Luo M, Zhao H, Dong L, et al: Characterization of
microRNA-29 family expression and investigation of their
mechanistic roles in gastric cancer. Carcinogenesis. 35:497–506.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Cui H, Wang L, Gong P, Zhao C, Zhang S,
Zhang K, Zhou R, Zhao Z and Fan H: Deregulation between miR-29b/c
and DNMT3A is associated with epigenetic silencing of the CDH1
gene, affecting cell migration and invasion in gastric cancer. PLoS
One. 10:e01239262015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhao X, Hou Y, Tuo Z and Wei F:
Application values of miR-194 and miR-29 in the diagnosis and
prognosis of gastric cancer. Exp Ther Med. 15:4179–4184.
2018.PubMed/NCBI
|
|
35
|
Wang D, Fan Z, Liu F and Zuo J: Hsa-miR-21
and Hsa-miR-29 in tissue as potential diagnostic and prognostic
biomarkers for gastric cancer. Cell Physiol Biochem. 37:1454–1462.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhang H, Bai M, Deng T, Liu R, Wang X, Qu
Y, Duan J, Zhang L, Ning T, Ge S, et al: Cell-derived microvesicles
mediate the delivery of miR-29a/c to suppress angiogenesis in
gastric carcinoma. Cancer Lett. 375:331–339. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wu J, Li L and Jiang C: Identification and
Evaluation of Serum MicroRNA-29 Family for Glioma Screening. Mol
Neurobiol. 52:1540–1546. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Parpart S, Roessler S, Dong F, Rao V,
Takai A, Ji J, Qin LX, Ye QH, Jia HL, Tang ZY and Wang XW:
Modulation of miR-29 expression by alpha-fetoprotein is linked to
the hepatocellular carcinoma epigenome. Hepatology. 60:872–883.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wei M, Yang T, Chen X, Wu Y, Deng X, He W,
Yang J and Wang Z: Malignant ascites-derived exosomes promote
proliferation and induce carcinoma-associated fibroblasts
transition in peritoneal mesothelial cells. Oncotarget.
8:42262–42271. 2017.PubMed/NCBI
|
|
40
|
Deng G, Qu J, Zhang Y, Che X, Cheng Y, Fan
Y, Zhang S, Na D, Liu Y and Qu X: Gastric cancer-derived exosomes
promote peritoneal metastasis by destroying the mesothelial
barrier. FEBS Lett. 591:2167–2179. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
van Rooij E, Sutherland LB, Thatcher JE,
DiMaio JM, Naseem RH, Marshall WS, Hill JA and Olson EN:
Dysregulation of microRNAs after myocardial infarction reveals a
role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci USA.
105:13027–13032. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Roderburg C, Urban GW, Bettermann K, Vucur
M, Zimmermann H, Schmidt S, Janssen J, Koppe C, Knolle P, Castoldi
M, et al: Micro-RNA profiling reveals a role for miR-29 in human
and murine liver fibrosis. Hepatology. 53:209–218. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Cushing L, Kuang PP, Qian J, Shao F, Wu J,
Little F, Thannickal VJ, Cardoso WV and Lü J: miR-29 is a major
regulator of genes associated with pulmonary fibrosis. Am J Respir
Cell Mol Biol. 45:287–294. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Yu JW, Duan WJ, Huang XR, Meng XM, Yu XQ
and Lan HY: MicroRNA-29b inhibits peritoneal fibrosis in a mouse
model of peritoneal dialysis. Lab Invest. 94:978–990. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Sasako M, Sakuramoto S, Katai H, Kinoshita
T, Furukawa H, Yamaguchi T, Nashimoto A, Fujii M, Nakajima T and
Ohashi Y: Five-year outcomes of a randomized phase III trial
comparing adjuvant chemotherapy with S-1 versus surgery alone in
stage II or III gastric cancer. J Clin Oncol. 29:4387–4393. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Noh SH, Park SR, Yang HK, Chung HC, Chung
IJ, Kim SW, Kim HH, Choi JH, Kim HK, Yu W, et al: Adjuvant
capecitabine plus oxaliplatin for gastric cancer after D2
gastrectomy (CLASSIC): 5-year follow-up of an open-label,
randomised phase 3 trial. Lancet Oncol. 15:1389–1396. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Wang X, Zhang H, Yang H, Bai M, Ning T, Li
S, Li J, Deng T, Ying G and Ba Y: Cell-derived exosomes as
promising carriers for drug delivery and targeted therapy. Curr
Cancer Drug Targets. 18:347–354. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Maheshwari R, Tekade M, Gondaliya P, Kalia
K, D'Emanuele A and Tekade RK: Recent advances in exosome-based
nanovehicles as RNA interference therapeutic carriers. Nanomedicine
(Lond). 12:2653–2675. 2017. View Article : Google Scholar : PubMed/NCBI
|
